Comparison of Efficacy of Intravitreal Aflibercept and Ranibizumab in Treatment-naive Diabetic Macular Edema
Journal Title: European Archives of Medical Research - Year 2019, Vol 35, Issue 3
Abstract
Objective: The purpose of this study was to compare the efficacy of two different intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in two treatment-naive and statistically equal cohorts of diabetic macular edema patients. Methods: In this retrospective study, 81 eyes of 64 treatment-naive diabetic macular edema (DME) patients were enrolled. Patients were divided into two groups and both groups were treated [37 eyes with intravitreal 0.5 mg ranibizumab (IVR) and 44 eyes with intravitreal 2 mg aflibercept (IVA)] with three consecutive injections at intervals of one month. All patients underwent a detailed eye examination including optic coherence tomography and best corrected visual acuity (BCVA; Snellen), biomicroscopy, fundoscopy and applanation tonometry at preoperative, 1st, 2nd and 3rd month. BCVA values were converted into logarithm of the minimum angle of resolution (logMAR) for statistical analyses. Data were evaluated with SPSS 25.0. Results: Mean BCVA (logMAR) increased from 0.58±0.28 to 0.43±0.29, 0.39±0.25 and 0.32±0.26 (p=0.001, p<0.001, p<0.001) in the IVR group and from 0.54±0.28 to 0.41±0.34, 0.43±0.39 and to 0.32±0.37 (p=0.004, p=0.023, p<0.001) in the IVA group. Mean central macular thickness (CMT) decreased from 406±82 μm to 345±65 μm (1st month), 332±83 μm (2nd month) and finally to 303±60 μm (3rd month) (p<0.001) in the IVR group and from 415±88 μm to 328±79 μm, 297±54 μm and finally to 277±54 μm (p<0.001) in the IVA group, respectively. There was no significant difference between the groups in terms of BCVA (p>0.05). In the subgroup analysis, CMT gain in patients with moderate DME (CMT ≤385 μm) was found significantly better in the IVA group compared to the IVR group (1st month: 36.9 vs. 83.6, 2nd month: 36.2 vs. 106.3, 3rd month: 3nd 72.7 vs. 125.1; p<0.05). Conclusion: Both anti-VEGFs were equally effective in visual outcomes. Compared to ranibizumab, aflibercept has a rapid and superior therapeutic effect in anatomical results, especially in moderate DME cases.
Authors and Affiliations
Burak Erden, Akın Çakır, Selim Bölükbaşı, Ali Cihat Aslan, Mustafa Nuri Elçioğlu
Keywords
Related Articles
- EP ID EP549065
- DOI 10.4274/eamr.galenos.2019.72792
- Views 199
- Downloads 0
Evaluation of Echocardiographic Findings of Mucopolysaccharidosis Cases
Objective: Mucopolysaccharidosis (MPS) is a lysosomal storage disease in which the degradation of glycosaminoglycans is impaired. Cardiac involvement may occur in different ways in all types of the disease. In this study...
PSMA-positive Secondary Tumors in 68Ga-PSMA PET/CT Imaging in Patients with Prostate Cancer
Objective: The objective of this research was to examine the prostate-specific membrane antigen (PSMA)-positive secondary tumor incidence in 68Ga-PSMA positron emission tomography/computed tomography (PET/CT) imaging in...
The Awareness of Venous Thromboembolism and Its Prophylaxis: A Survey Study
Objective: The purpose of this questionnaire study was to present the results of venous thromboembolism (VTE) questionnaire and compare the data with the literature by having information about awareness level of VTE in a...
Extracorporeal Membrane Oxygenation for Pulmonary Embolism During Pregnancy and Postpartum
The maternal and fetal mortality rate in unstable pulmonary embolisms accompanied by obstructive cardiac shock is approximately 30%. An intervention aimed at the pulmonary clot is essential under these conditions. There...
Non-urothelial Bladder Cancers: Single Center Experience
Objective: Bladder cancers are classified into two groups as urothelial and non-urothelial cancer (NUBC). In this study, we investigated the clinicopathological features and treatment responses in patients with NUBC who...